Compare Stocks: EVOK, SPRO, TLPH, and LONA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
LONA Athira Pharma	$7.47 +5.8%	$8.46	$3.52 ▼ $14.21	$70.17M	2.01	52,089 shs	11,024 shs
SPRO Spero Therapeutics	$1.15 -1.7%	$2.16	$1.08 ▼ $3.08	$66.59M	1.55	887,067 shs	1.37 million shs
TLPH Talphera	$1.33 +3.9%	$1.08	$0.39 ▼ $1.57	$69.03M	0.69	246,376 shs	120,466 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+134.54%
LONA Athira Pharma	0.00%	-4.47%	-20.41%	-26.07%	+705,999,900.00%
SPRO Spero Therapeutics	0.00%	-1.68%	-46.82%	-52.82%	-49.13%
TLPH Talphera	0.00%	-5.19%	+19.63%	+39.34%	+218.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$11.00 +0.4%	$10.90	$2.28 ▼ $11.00	$18.92M	-0.15	983,927 shs	47,100 shs
LONA Athira Pharma	$7.47 +5.8%	$8.46	$3.52 ▼ $14.21	$70.17M	2.01	52,089 shs	11,024 shs
SPRO Spero Therapeutics	$1.15 -1.7%	$2.16	$1.08 ▼ $3.08	$66.59M	1.55	887,067 shs	1.37 million shs
TLPH Talphera	$1.33 +3.9%	$1.08	$0.39 ▼ $1.57	$69.03M	0.69	246,376 shs	120,466 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	0.00%	0.00%	0.00%	0.00%	+134.54%
LONA Athira Pharma	0.00%	-4.47%	-20.41%	-26.07%	+705,999,900.00%
SPRO Spero Therapeutics	0.00%	-1.68%	-46.82%	-52.82%	-49.13%
TLPH Talphera	0.00%	-5.19%	+19.63%	+39.34%	+218.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	1.50	Reduce	N/A	N/A
LONA Athira Pharma	2.50	Moderate Buy	$16.00	114.19% Upside
SPRO Spero Therapeutics	1.50	Reduce	N/A	N/A
TLPH Talphera	2.25	Hold	$3.00	125.56% Upside

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TLPH, and LONA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	TLPH Talphera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/5/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.00
5/27/2026	LONA Athira Pharma	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
5/11/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$10.25M	1.85	N/A	N/A	$4.74 per share	2.32
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SPRO Spero Therapeutics	$66.80M	1.00	$0.15 per share	7.69	$1.05 per share	1.10
TLPH Talphera	$30K	2,300.90	N/A	N/A	$0.37 per share	3.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$5.35M	-$2.07	N/A	N/A	N/A	-36.23%	-101.40%	-31.86%	N/A
LONA Athira Pharma	-$105.61M	-$5.21	N/A	N/A	N/A	N/A	-381.01%	-225.74%	N/A
SPRO Spero Therapeutics	$8.57M	$0.24	4.79	N/A	N/A	24.90%	35.58%	24.95%	8/11/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.31	N/A	N/A	N/A	N/A	-92.98%	-53.22%	8/13/2026 (Estimated)

Latest EVOK, SPRO, TLPH, and LONA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TLPH Talphera	-$0.07	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	N/A	N/A	N/A	$0.28 million	N/A
5/13/2026	Q1 2026	SPRO Spero Therapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$0.26 million	$0.26 million
5/13/2026	Q1 2026	TLPH Talphera	-$0.07	-$0.04	+$0.03	-$0.04	N/A	N/A
5/7/2026	Q1 2026	LONA Athira Pharma	N/A	-$1.73	N/A	-$1.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	1.27	1.22
LONA Athira Pharma	N/A	10.38	10.38
SPRO Spero Therapeutics	N/A	10.50	10.50
TLPH Talphera	N/A	5.30	5.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
LONA Athira Pharma	57.12%
SPRO Spero Therapeutics	25.60%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	2.29%
LONA Athira Pharma	25.73%
SPRO Spero Therapeutics	2.90%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	1.72 million	1.68 million	Not Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
SPRO Spero Therapeutics	150	57.90 million	56.22 million	Optionable
TLPH Talphera	19	51.90 million	50.08 million	Optionable

EVOK, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

Talphera (NASDAQ:TLPH) Shares Down 1.5% - Here's What Happened

July 24, 2026 | marketbeat.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | finanznachrichten.de

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

Talphera Q1 2026 Earnings Call Transcript

May 13, 2026 | finance.yahoo.com

Talphera targets Niyad PMA filing in 2026 and potential approval in 2027 as NEPHRO enrollment surpasses 50%

May 13, 2026 | seekingalpha.com

Talphera (TLPH) Q1 2026 Earnings Transcript

May 13, 2026 | fool.com

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

May 7, 2026 | prnewswire.com

WestPark Capital initiates coverage of Talphera (TLPH) with buy recommendation

May 1, 2026 | msn.com

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC), Talphera (TLPH) and Abivax SA Sponsored ADR (ABVX)

March 26, 2026 | theglobeandmail.com

Talphera (NASDAQ:TLPH) CEO Acquires $125,852.90 in Stock

March 26, 2026 | insidertrades.com

Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

March 25, 2026 | prnewswire.com

Talphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 24, 2026 | finanznachrichten.de

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

March 24, 2026 | seekingalpha.com

Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 23, 2026 | prnewswire.com

Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

March 18, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EVOK, SPRO, TLPH, and LONA Company Descriptions

Evoke Pharma NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Athira Pharma NASDAQ:LONA

$7.47 +0.41 (+5.81%)

Closing price 04:00 PM Eastern

Extended Trading

$7.52 +0.04 (+0.60%)

As of 04:54 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Spero Therapeutics NASDAQ:SPRO

$1.15 -0.02 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 +0.01 (+0.43%)

As of 05:06 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Talphera NASDAQ:TLPH

$1.33 +0.05 (+3.91%)

Closing price 04:00 PM Eastern

Extended Trading

$1.33 +0.00 (+0.08%)

As of 04:28 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TLPH, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, SPRO, TLPH, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVOK, SPRO, TLPH, and LONA Company Descriptions

Evoke Pharma NASDAQ:EVOK

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVOK, SPRO, TLPH, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVOK, SPRO, TLPH, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVOK, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVOK, SPRO, TLPH, and LONA Company Descriptions

Evoke Pharma NASDAQ:EVOK

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools